Stem cell startup Thymmune lands $37M from Biden's ARPA-H for immune-rejuvenating therapies
The Biden administration is awarding up to $37 million to Thymmune Therapeutics, the Advanced Research Projects Agency for Health (ARPA-H) announced Thursday. The biotech startup uses stem cells to develop thymus-rejuvenating therapies.
Thymmune’s new funding comes amid a busy week for ARPA-H, a new research agency that the Biden administration established last year to fund big swings at biomedicine’s toughest problems.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.